Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics

Exclusion Criteria

• •Pregnant patients
• •Patients who because of general medical or psychiatric condition, or physiologic status unrelated to the presence of ovarian cancer cannot give valid informed consent
• •Patients who are unwilling or unable to undergo MRI including patients with contraindications to MRI such as the presence of cardiac pacemakers or non-compatible intracranial vascular clips, claustrophobia, inability to lie flat for the duration of the study etc.
• •Patients with a metallic hip implant or any other metallic implant or device in the pelvis that might distort local magnetic field and compromise quality of MRI/
• •Patients with synchronous primary endometrial cancer or a past history of endometrial cancer, unless all of the following conditions are met:
• •Stage not greater than IB
• •No more than superficial myometrial invasion
• •No vascular or lymphatic invasion
• •No poorly differentiated subtypes, including serous, clear cell, or other FIGO Grade 3 lesions.
• •Patients who have received prior chemotherapy for any abdominal or pelvic tumor are excluded. Patients who have received neoadjuvant chemotherapy prior to their initial debulking are excluded. Patients may have received prior adjuvant chemotherapy for breast cancer.
• •With the exception of non-melanoma skin cancer and other specific malignancies as noted above, subjects with other invasive malignancies who had (or have) any evidence of the other cancer present within the last 3 years are excluded.
• •Unresolved bowel obstruction.
• •History or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with patient's participation for the full duration of the study.
• •Absence of target lesions (\> 2.0 cm) on staging CT
• •Patients unlikely to be optimally debulked at surgery (tumor implants in difficult to reach places \[i.e. falciform ligament or porta hepatis\], suprarenal retroperitoneal lymphadenopathy)